Sanofi sells rare disease drug Enjaymo to Recordati for $825 million upfront – Endpoints News

Posted on October 4, 2024 by Vaseline

Sanofi sells rare disease drug Enjaymo to Recordati for 5 million upfront – Endpoints News

Sanofi is transferring its rare autoimmune disease drug Enjaymo to an Italian pharmaceutical company for $825 million upfront.

Recordati, based in Milan,

Sign up to read this article for free.

Get free access to a limited number of articles and opt for newsletters sent directly to your inbox.